Incidental Lewy body disease: do some cases represent a preclinical stage of dementia with Lewy bodies?

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Neurobiology of Aging

• Publication date

  2011-05-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/j.neurobiolaging.2009.05.019PMID 19560232PMCID PMC3366193
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Critical evaluation of the Braak staging scheme for Parkinson's disease

  2010influential reference
• Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction

  2009cited by this paper
• Patterns and stages of α-synucleinopathy

  2008cited by this paper
• Applicability of current staging/categorization of α-synuclein pathology and their clinical relevance

  2008influential reference
• A critical evaluation of the Braak staging scheme for Parkinson's disease

  2008cited by this paper
• The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease

  2008influential reference
• Evaluation of alpha-synuclein immunohistochemical methods used by invited experts.

  2008cited by this paper
• Incidental Lewy body disease and preclinical Parkinson disease.

  2008cited by this paper
• Empiric refinement of the pathologic assessment of Lewy-related pathology in the dementia patient.

  2008cited by this paper
• A critical reappraisal of current staging of Lewy-related pathology in human brain

  2008cited by this paper
• The progression of pathology in longitudinally followed patients with Parkinson’s disease

  2008influential reference
• Validation of the Neuropathologic Criteria of the Third Consortium for Dementia With Lewy Bodies for Prospectively Diagnosed Cases

  2008cited by this paper
• Reduced striatal tyrosine hydroxylase in incidental Lewy body disease

  2008cited by this paper
• The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease: a critical analysis of α‐synuclein staging

  2008influential reference
• Parkinson's disease: a dual‐hit hypothesis

  2007cited by this paper
• DLB and PDD boundary issues

  2007cited by this paper
• Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies.

  2007cited by this paper
• Clinical diagnostic criteria for dementia associated with Parkinson's disease

  2007cited by this paper
• Parkinson’s disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons

  2007cited by this paper
• Presynaptic α-Synuclein Aggregates, Not Lewy Bodies, Cause Neurodegeneration in Dementia with Lewy Bodies

  2007cited by this paper
• α‐Synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects

  2006influential reference
• Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology.

  2006cited by this paper
• Alzheimer Disease With Amygdala Lewy Bodies: A Distinct Form of &agr;-Synucleinopathy

  2006cited by this paper
• Alpha-synuclein pathology in the spinal cords of neurologically asymptomatic aged individuals.

  2006cited by this paper
• Diagnosis and management of dementia with Lewy bodies

  2005cited by this paper
• Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium

  2005cited by this paper
• Dementia with Lewy bodies and Parkinson's disease with dementia: are they different?

  2005cited by this paper
• Neuropathology of dementia in Parkinson's disease: A prospective, community‐based study

  2005influential reference
• α-synuclein pathology does not predict extrapyramidal symptoms or dementia

  2005influential reference
• α‐Synuclein pathology does not predict extrapyramidal symptoms or dementia

  2005influential reference
• Are Parkinson’s Disease with dementia and Dementia with lewy Bodies the Same Entity?

  2004cited by this paper
• Stages in the development of Parkinson’s disease-related pathology

  2004cited by this paper
• Neuropathological stageing of Alzheimer-related changes

  2004cited by this paper
• α-Synuclein pathology in Parkinson’s and Alzheimer’s disease brain: incidence and topographic distribution—a pilot study

  2003cited by this paper
• Staging of brain pathology related to sporadic Parkinson's disease.

  2003cited by this paper
• α-Synuclein pathology in Parkinson’s and Alzheimer’s disease brain: incidence and topographic distribution—a pilot study

  2003cited by this paper
• Accumulation of Phosphorylated α‐Synuclein in Aging Human Brain

  2003cited by this paper
• Accumulation of phosphorylated alpha-synuclein in aging human brain.

  2003cited by this paper
• Risk tables for parkinsonism and Parkinson's disease.

  2002cited by this paper
• Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response.

  2002cited by this paper
• Lewy Bodies in Alzheimer's Disease: A Neuropathological Review of 145 Cases Using α‐Synuclein Immunohistochemistry

  2000cited by this paper
• Cell death or synaptic loss in Alzheimer disease.

  2000cited by this paper
• Distinctive neuropathology revealed by α-synuclein antibodies in hereditary parkinsonism and dementia linked to chromosome 4p

  2000cited by this paper
• Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease

  2000influential reference
• Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease.

  1997cited by this paper
• An anatomy of the autopsy, Olmsted County, 1935 through 1985.

  1989cited by this paper
• The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.

  1988cited by this paper
• Assessing the autopsy.

  1987cited by this paper
• Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree--a new disease?

  1984influential reference

• Alpha-Synuclein in Neurodegeneration: From Shared Biology to Disease-Specific Phenotypes

  2026cites this paper
• A split biotin ligase approach reveals proteins associated with oligomeric alpha-synuclein during aggregation

  2026cites this paper
• A Split Biotin Ligase Approach to Revealing Proteins Associated with Oligomeric Alpha-Synuclein During Aggregation

  2025cites this paper
• The temporal order of genetic, environmental, and pathological risk factors in Parkinson's disease: paving the way to prevention.

  2025cites this paper
• Synaptic enrichment of pSer129 alpha-synuclein correlates with dopaminergic denervation in early-stage Parkinson’s disease

  2025cites this paper
• Identification of Common Brain Protein and Genetic Loci Between Parkinson's Disease and Lewy Body Dementia

  2025cites this paper
• Novel in situ seeding immunodetection assay uncovers neuronal-driven alpha-synuclein seeding in Parkinson’s disease

  2025cites this paper
• Brain-derived tau oligomer polymorphs: distinct aggregations, stability profiles, and biological activities

  2025cites this paper
• Where do PDD and DLB SYNdromes fit in neuronal alpha-SYNuclein biological frameworks?

  2025cites this paper
• Sociodemographic correlates of cognition and Alzheimer's disease and vascular biomarkers among middle to older age participants in the Healthy Brain Initiative

  2025cites this paper
• A Novel PINK1 p.F385S Loss‐of‐Function Mutation in an Indian Family with Parkinson's Disease

  2024cites this paper
• Accumulation of Lewy‐Related Pathology Starts in Middle Age: The Tampere Sudden Death Study

  2024cites this paper
• Parkinson's disease progression is multifaceted: Evidence for the underlying benchmarks.

  2024cites this paper
• Predicting Post‐Mortem α‐Synuclein Pathology by the Combined Presence of Probable REM sleep behavior disorder and Hyposmia

  2024cites this paper
• Modeling Parkinson’s disease pathology in human dopaminergic neurons by sequential exposure to α-synuclein fibrils and proinflammatory cytokines

  2024cites this paper
• Unveiling the link: hepatitis C virus and Parkinson’s disease

  2024cites this paper
• Performance of a seed amplification assay for misfolded alpha-synuclein in cerebrospinal fluid and brain tissue in relation to Lewy body disease stage and pathology burden

  2024cites this paper
• Conjugal Synucleinopathies: A Clinicopathologic Study

  2024cites this paper
• Altered TFEB subcellular localization in nigral neurons of subjects with incidental, sporadic and GBA-related Lewy body diseases

  2024cites this paper
• Neurodegeneration, Mitochondria, and Antibiotics

  2023cites this paper
• Neuroinflammatory Part of the Systemic Inflammatory Process in the Development of Neurodegenerative Conditions

  2023cites this paper
• Could the Urease of the Gut Bacterium Proteus mirabilis Play a Role in the Altered Gut–Brain Talk Associated with Parkinson’s Disease?

  2023cites this paper
• Aggregation of alpha-synuclein disrupts mitochondrial metabolism and induce mitophagy via cardiolipin externalization

  2023cites this paper
• Role of microglia autophagy and mitophagy in age-related neurodegenerative diseases

  2023cites this paper
• A dual hit of α-synuclein internalization and immune challenge leads to formation and maintenance of Lewy body-like inclusions in human dopaminergic neurons Running title: Lewy body-like inclusions in dopaminergic neurons

  2023cites this paper
• Beyond the Microbiota: Understanding the Role of the Enteric Nervous System in Parkinson’s Disease from Mice to Human

  2023cites this paper
• Altered TFEB subcellular localization in nigral dopaminergic neurons of subjects with prodromal, sporadic and GBA-related Parkinson’s disease and Dementia with Lewy bodies

  2023cites this paper
• Activation of the Mitochondrial Unfolded Protein Response: A New Therapeutic Target?

  2022cites this paper
• One Autopsy Proved Neocortical Lewy Body Disease Without the Involvement of the Olfactory Bulb and Brainstem

  2022cites this paper
• Strong Predictive Algorithm of Pathogenesis-Based Biomarkers Improves Parkinson’s Disease Diagnosis

  2022cites this paper
• Characterizing Lewy Pathology in 231 Essential Tremor Brains From the Essential Tremor Centralized Brain Repository.

  2022cites this paper
• Rainwater Charitable Foundation criteria for the neuropathologic diagnosis of progressive supranuclear palsy

  2022cites this paper
• Recent advances in Lewy body dementia: A comprehensive review.

  2022cites this paper
• The O-Glycome of Human Nigrostriatal Tissue and Its Alteration in Parkinson’s Disease

  2021cites this paper
• An Autopsy-Proven Case of Lewy Body Disease Presenting with Severe Dysphagia

  2021cites this paper
• The Logic and Pitfalls of Parkinson's Disease as “Brain‐First” Versus “Body‐First” Subtypes

  2021cites this paper
• Etiology and pathogenesis of Parkinson disease

  2021cites this paper
• Examining the Toxicity of α-Synuclein in Neurodegenerative Disorders

  2021cites this paper
• Identification of multiple system atrophy mimicking Parkinson’s disease or progressive supranuclear palsy

  2021cites this paper
• Parkinson's disease

  2021cites this paper
• Genetic Variations and Neuropathologic Features of Patients with PRKN Mutations

  2021cites this paper
• Lipids, lysosomes and mitochondria: insights into Lewy body formation from rare monogenic disorders

  2021cites this paper
• Insights into Lewy body disease from rare neurometabolic disorders

  2021cites this paper
• An autopsy case of PARK2 due to a homozygous exon 2 deletion of parkin and associated with α‐synucleinopathy

  2021influential citation
• Negative α-synuclein pathology in the submandibular gland of patients carrying PRKN pathogenic variants.

  2020cites this paper
• Novel approaches to counter protein aggregation pathology in Parkinson's disease.

  2020cites this paper
• When does cerebral β‐amyloid deposition begin in Lewy body dementia?

  2020cites this paper
• Pathological Influences on Clinical Heterogeneity in Lewy Body Diseases

  2020cites this paper
• Innate and adaptive immune responses in Parkinson's disease.

  2020cites this paper
• Considerations for trials of disease modifying treatments in Parkinson disease

  2020cites this paper
• Overexpression of alpha-synuclein promotes both cell proliferation and cell toxicity in human SH-SY5Y neuroblastoma cells

  2020cites this paper
• Salivary alpha-synuclein (total and oligomeric form): potential biomarkers in Parkinson’s disease

  2020cites this paper
• A Parkinson-kórhoz társuló demencia és a Lewy-testes demencia patológiai és klinikai összehasonlítása Pathological and clinical comparison of Parkinson’s disease dementia and dementia with Lewy bodies

  2020cites this paper
• Neuroinflammation and Alpha-Synuclein Oligomer Toxicity in the Pathogenesis of Lewy Body Dementia and Parkinson's Disease

  2020cites this paper
• Treating Parkinson’s Disease with Antibodies: Previous Studies and Future Directions

  2020cites this paper
• Cysteine 343 in the Substrate Binding Domain is the Primary S-Nitrosylated Site in Protein Disulfide Isomerase.

  2020cites this paper
• Characterization and validation of 16 α-synuclein conformation-specific antibodies using well-characterized preparations of α-synuclein monomers, fibrils and oligomers with distinct structures and morphology: How specific are the conformation-specific α-synuclein antibodies?

  2020cites this paper
• Associations of sleep characteristics with alpha‐synuclein in cerebrospinal fluid in older adults

  2020cites this paper
• Where and how alpha‐synuclein pathology spreads in Parkinson’s disease:

  2020cites this paper
• [A Parkinson-kórhoz társuló demencia és a Lewy-testes demencia patológiai és klinikai összehasonlítása].

  2020cites this paper
• Dementia with Lewy bodies - a clinicopathological update.

  2020cites this paper
• Emerging therapies in Parkinson disease — repurposed drugs and new approaches

  2019cites this paper
• Unique α-synuclein pathology within the amygdala in Lewy body dementia: implications for disease initiation and progression

  2019cites this paper
• The dysfunctional brain dynamic of Lewy body dementia and its behavioural and clinical correlates : an fMRI and EEG analysis

  2019cites this paper
• Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update—I. Hypokinetic-rigid movement disorders

  2019cites this paper
• Antibodies against alpha‐synuclein: tools and therapies

  2019cites this paper
• Lewy Body Disease

  2019cites this paper
• Imaging in prodromal dementia with Lewy bodies: Where do we stand?

  2019cites this paper
• α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis.

  2019cites this paper
• Lewy body pathology is more prevalent in older individuals with mitochondrial disease than controls

  2019cites this paper
• Is There a Shared Etiology of Olfactory Impairments in Normal Aging and Neurodegenerative Disease?

  2019cites this paper
• Unified Staging System for Lewy Body Disorders: Clinicopathologic Correlations and Comparison to Braak Staging.

  2019cites this paper
• When Do &agr;-Synucleinopathies Start? An Epidemiological Timeline: A Review

  2018cites this paper
• Apolipoprotein E polymorphism and hippocampal atrophy across the spectrum of Alzheimer’s disease and dementia with Lewy bodies

  2018cites this paper
• Predicting alpha-synuclein pathology by REM sleep behavior disorder diagnosis.

  2018cites this paper
• Is Lewy pathology in the human nervous system chiefly an indicator of neuronal protection or of toxicity?

  2018cites this paper
• Diffuse Lewy body disease manifesting as corticobasal syndrome

  2018cites this paper
• Is Braak staging valid for all types of Parkinson’s disease?

  2018cites this paper
• REM Sleep Behavior Disorder (RBD) in Dementia with Lewy Bodies (DLB)

  2018cites this paper
• Oligodendrogliopathy in neurodegenerative diseases with abnormal protein aggregates: The forgotten partner.

  2018influential citation
• Dementia with Lewy bodies and Parkinson’s disease-dementia: current concepts and controversies

  2018cites this paper
• Are dementia with Lewy bodies and Parkinson’s disease dementia the same disease?

  2018cites this paper
• Implication of Alpha-synuclein Transcriptional Regulation and Mutagenesis in the Pathogenesis of Sporadic Parkinson's Disease

  2017cites this paper
• Neuropathological Staging of Brain Pathology in Sporadic Parkinson’s disease: Separating the Wheat from the Chaff

  2017cites this paper
• Alpha-synuclein oligomers: a new hope

  2017cites this paper
• Dementia with Lewy Bodies

  2017cites this paper
• Pathology of Neurodegenerative Diseases.

  2017cites this paper
• Neuropathology of Nonmotor Symptoms of Parkinson's Disease.

  2017cites this paper
• Ginkgolide B and bilobalide ameliorate neural cell apoptosis in α-synuclein aggregates.

  2017cites this paper
• α-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies

  2017cites this paper
• Rapid eye movement sleep without atonia may help diagnose Lewy body disease in middle‐aged and older patients with somatic symptom disorder

  2017cites this paper
• Enteric Pathologic Manifestations of Alpha-Synucleinopathies

  2017cites this paper
• Cognitive and Neuropsychiatric Features in Parkinson's and Lewy Body Dementias.

  2017cites this paper
• GDNF and Neurturin isoforms in an experimental model of Parkinson's disease

  2017cites this paper
• Gene therapy for Parkinson's disease: Disease modification by GDNF family of ligands.

  2017cites this paper
• Lack of spontaneous age-related brain pathology in Octodon degus: a reappraisal of the model

  2017cites this paper
• The olfactory bulb as the entry site for prion-like propagation in neurodegenerative diseases

  2016influential citation
• Metals in Alzheimer’s and Parkinson’s Disease: Relevance to Dementia with Lewy Bodies

  2016cites this paper
• Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders

  2016cites this paper
• Biomarkers in dementia with Lewy bodies

  2016cites this paper